Poster Tour: Basic Science
| Thursday, September 19, 2019 |
| 12:15 PM - 12:45 PM |
Speaker
Mr Damien Fagan
Associate Director, Medical Affairs
Gilead Sciences Pty Ltd
#6 HIGH LEVEL OF PRE-EXISTING NRTI RESISTANCE PRIOR TO SWITCHING TO BIC/FTC/TAF (STUDY 4030)
12:15 PM - 12:20 PMBiography
Paul graduated from Cambridge University, has MRCP(UK) and MBA from London Business School. He joined BMS in 1997 working in Europe, Australia, and US before joining Janssen in 2012 where he had Asia-Pacific responsibilities. In October 2015 Paul joined Gilead ANZ as Medical Director and is currently acting General Manager
Mr Damien Fagan
Associate Director, Medical Affairs
Gilead Sciences Pty Ltd
#4 LONG TERM B/F/TAF SWITCH EFFICACY IN PATIENTS WITH ARCHIVED PREEXISTING RESISTANCE
12:20 PM - 12:25 PMBiography
I am a registered pharmacist with over 16 years working in HIV & sexual health in both the UK and Australia, clinically and in academia. I have an interest advocating for marginalised and vulnerable groups in accessing equitable healthcare. I am now working with medical affairs at Gilead Sciences.
Mr Damien Fagan
Associate Director, Medical Affairs
Gilead Sciences Pty Ltd
#5 FORGIVENESS OF ANTIRETROVIRAL REGIMENS: IN VITRO HIV-1 VIRAL BREAKTHROUGH WITH 2-DRUG VERSUS 3-DRUG REGIMENS SIMULATING VARIABLE ADHERENCE TO TREATMENT
12:25 PM - 12:30 PMBiography
I am a registered pharmacist with over 16 years working in HIV & sexual health in both the UK and Australia, clinically and in academia. I have an interest advocating for marginalised and vulnerable groups in accessing equitable healthcare. I am now working with medical affairs at Gilead Sciences.
Lloyd DÓrsogna
Lloyd DÓrsogna
Facilitator
Patricia Price
Principal Research Fellow
Curtin university
